Illumina, Inc.
Illumina Reports Q3 2025 Financial Results and Updates Guidance
Summary
Illumina, Inc. reported its financial results for the third quarter of fiscal year 2025, showing flat revenue of $1.08 billion on both a reported and constant currency basis compared to Q3 2024. The company reported a GAAP operating margin of 21.0% and a non-GAAP operating margin of 24.5%. GAAP diluted EPS was $0.98, while non-GAAP diluted EPS was $1.34. Additionally, Illumina updated its guidance for fiscal year 2025, raising the expected range for non-GAAP diluted EPS from $4.45 - $4.55 to $4.65 - $4.75. Free cash flow for the quarter was $253 million. Key financial details are included in the press release and the accompanying financial statements.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement